Yanmei Xu

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

J. Sosman, A. Ribas, P. Hwu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers

Yanmei Xu, A. Lockhart, X. Yao, 2016, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics, Safety, and Tolerability of Lamotrigine Chewable/Dispersible Tablet Following Repeat‐Dose Administration in Healthy Chinese Volunteers

Yanmei Xu, Huafang Li, Yan Li, 2018, Clinical pharmacology in drug development.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, L. Hart, 2012, The Lancet. Oncology.

Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

Yanmei Xu, D. Sprecher, J. Lepore, 2014, PloS one.

Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [18F]GSK2647544 in Healthy Male Subjects

J. Passchier, E. Rabiner, Yanmei Xu, 2016, Molecular Imaging and Biology.

Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors.

Ying Cheng, Yanmei Xu, Z. Shao, 2016 .

An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers

Yanmei Xu, G. Collins, R. Mohindra, 2015, Journal of clinical pharmacology.

A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

P. Bonate, P. LoRusso, R. Kurzrock, 2012, Investigational New Drugs.